Trial results

Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus

NCT03011008 on ClinicalTrials.gov · last registry update 2020-03-18

A small phase 4 — 20 participants, against a typical 75. Its estimated completion date, December 2020, has passed with no update to the record. Primary outcome, as filed: Mean amplitude of glycemic excursions (MAGE). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

UNKNOWN

Phase

P4

Drug

liraglutide

Saxenda, Victoza, Xultophy

Sponsor

Second Xiangya Hospital of Central South University

Sponsor type

Other

Enrollment

20

Started

2017-01

Primary completion

2020-12 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Mean amplitude of glycemic excursions (MAGE)

Conditions studied

Type 1 Diabetes Mellitus · Autoimmune Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.